早期乳腺癌保乳术后大分割调强放疗与常规放疗的临床疗效比较

Comparison of Clinical Efficacy of Intensity-modulated Radiotherapy and Conventional Radiotherapy after Breast-conserving Surgery for Early Breast Cancer

目的探究早期乳腺癌保乳术后大分割调强放疗与常规放疗的临床疗效。方法 2017年5月—2019年5月期间共方便选取该科室96例早期乳腺癌保乳术患者进行该次研究,按照选用时间先后顺序将其分为两组,对比组48例(2017年5月—2018年4月),研究组48例(2018年5月—2019年5月),对比组进行常规放疗,研究组进行大分割调强放疗,分析两组的不良反应发生状况、美容效果以及随访局部控制率数据。结果研究组共发生不良反应28次(58.33%),低于对比组不良反应45次(93.75%),差异有统计学意义(χ^2=16.521,P<0.001);研究组美容效果优良率高于对比组差异有统计学意义(P<0.05);研究组局部控制率为97.92%,仅有1例在治疗后4个月发生转移,优于对比组差异有统计学意义(χ^2=3.852,P<0.05)。结论在早期乳腺癌保乳术后进行大分割调强放疗,能够更好地达到美容效果,提升局部控制率,且产生的不良反应较少,在实际临床中的运用价值较高。

Objective To explore the clinical effects of intensity-modulated radiotherapy and conventional radiotherapy after breast-conserving surgery for early breast cancer. Methods From May 2017 to May 2019, a total of convenient selection 96 patients with early breast cancer surgery in the undergraduate department were selected for this study. The subjects were divided into two groups in chronological order, and 48 cases in the comparison group(May 2017 to April 2018), 48 patients in the study group(May 2018 to May 2019), the control group received conventional radiotherapy, the study group received hyperfractionated intensity-modulated radiotherapy, and the occurrence of adverse reactions status, cosmetic effect and follow-up local control rate data in the two groups was analyzed. Results The study group had 28 adverse reactions 58.33%,which was lower than the control group’s 45 adverse reactions(93.75%), the difference was statistically significant(χ^2=16.521, P <0.001);the study group had a higher rate of cosmetic effects than the comparison Group,the difference was statistically significant(P<0.05);The local control rate of the study group was 97.92%, and only 1 case had metastasis 4 months after treatment, which was better than the control group,the difference was statistically significant(χ^2=3.852, P <0.05). Conclusion Hypofractionated intensity-modulated radiotherapy after breast conserving surgery for early breast cancer can better achieve cosmetic effects, improve local control rate, and produce fewer adverse reactions. It has a higher value in actual clinical application.